Wegovy tablets and injections are FDA-approved in adults for: weight loss and weight management in adults with obesity or adults who are overweight and have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol) reducing major cardiovascular event risks (such as heart attack, stroke, or death) in adults with established CV disease and either obesity or overweight Wegovy injection is also FDA-approved for: weight loss and weight management patients with obesity who are 12 years and older non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), this is an accelerated approval
Initial consultation to discuss weight loss goals Counseling with Nurse to demonstrate proper injection technique A one-month supply of compounded Semaglutide or Tirzepatide as weekly injections Follow-up appointments with a provider to monitor weight, blood pressure, BMI and to adjust dosage if necessary
With Wegovy, patients have experienced an average weight reduction of 15% over 68 weeks
At baseline, these remarkably effective medications are tough to get unless you have type 2 diabetes
Phytotherapy Several phytochemicals have demonstrated activity against the SARS-CoV-2 through mechanisms such as viral entry inhibition, inhibition of replication enzymes, and virus release blockade 766
70,71 Additionally, the exploration of GLP-1R positive allosteric modulators (PAMs) offers a new regulatory approach that could enhance the therapeutic profile of small-molecule GLP-1R agonists
